Market Cap$34.37B
P/E26.59x
PEG Ratio2.43
Div yield—
Beta0.10
BIIB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)20.10%
Price vs S&P 500 (4W)7.52%
PEG Ratio2.43
VGM Score53.75
P/E Ratio (Annual)26.59x
BIIB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.03 | $3.60 | +77.38%(+$1.57) | |
| Q1 2026 | $2.95 | $3.57 | +20.93%(+$0.62) | |
| Q4 2025 | $1.62 | $1.99 | +23.18%(+$0.37) | |
| Q3 2025 | $3.88 | $4.81 | +23.88%(+$0.93) | |
| Q2 2025 | $3.88 | $5.47 | +40.97%(+$1.59) |
BIIB Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.80
3.82
3.86
3.91
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About Biogen Inc. Common Stock
Biogen is a biopharmaceutical company focused on neurodegenerative and rare diseases. Its revenue base is anchored by multiple sclerosis therapies (40% of 2025 revenue) and a CD20 collaboration with Roche (19%), though the MS franchise is declining. The company is diversifying through emerging treatments including Leqembi for Alzheimer's disease, Spinraza for spinal muscular atrophy, and programs addressing postpartum depression, Friedreich's ataxia, and amyotrophic lateral sclerosis.